Investigating amyloid-β (Aβ) status could offer clinical implications for the identification of and intervention for individuals at higher risk of dementia due to Alzheimer's disease (AD). The use of computerized cognitive tests has been considered valuable in detecting Aβ positivity.
Objective
This study aims to examine the predictive accuracy of the Seoul Cognitive Status Test (Seoul CST) for Aβ-positive mild cognitive impairment (Aβ+ MCI).
Methods
A total of 138 patients with MCI who completed the Seoul CST and underwent Aβ positron emission tomography (PET) were included in this study.
Results
Participants with Aβ+ MCI performed worse in the backward task of the Visual Span Test and all memory tasks except the immediate recall of the Word Place Association Test. The composite score was developed by averaging the age-, sex-, and education-adjusted Z-scores of the tasks showing significant differences between Aβ+ and Aβ- (Aβ-negative) MCI. This composite score exhibited adequate accuracy in distinguishing between Aβ+ and Aβ- MCI (area under the curve: 0.788, 95% confidence interval: 0.703–0.872).
Conclusions
The findings suggest that the Seoul CST may contribute to screening MCI patients who are likely to be Aβ+.
EllisKASzoekeCBushAI, et al.Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). Int Psychogeriatr2014; 26: 543–554.
2.
ScheltensPDe StrooperBKivipeltoM, et al.Alzheimer's disease. Lancet2021; 397: 1577–1590.
3.
CiarmielloATartaglioneAGiovanniniE, et al.Amyloid burden identifies neuropsychological phenotypes at increased risk of progression to Alzheimer's disease in mild cognitive impairment patients. Eur J Nucl Med Mol Imaging2019; 46: 288–296.
4.
DoraiswamyPMSperlingRAJohnsonK, et al.Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry2014; 19: 1044–1051.
5.
OkelloAKoivunenJEdisonP, et al.Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology2009; 73: 754–760.
6.
MintunMALoACDuggan EvansC, et al.Donanemab in early Alzheimer’s disease. N Engl J Med2021; 384: 1691–1704.
7.
SevignyJChiaoPBussièreT, et al.The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature2016; 537: 50–56.
8.
Van DyckCHSwansonCJAisenP, et al.Lecanemab in early Alzheimer’s disease. N Engl J Med2023; 388: 9–21.
9.
ÖhmanFHassenstabJBerronD, et al.Current advances in digital cognitive assessment for preclinical Alzheimer's disease. Alzheimers Dement (Amst)2021; 13: e12217.
10.
PappKVSamarooAChouHC, et al.Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease. Alzheimers Dement (Amst)2021; 13: e12243.
11.
NicosiaJAschenbrennerAJBalotaDA, et al.Unsupervised high-frequency smartphone-based cognitive assessments are reliable, valid, and feasible in older adults at risk for Alzheimer’s disease. J Int Neuropsychol Soc2023; 29: 459–471.
12.
AldenECPudumjeeSBLundtES, et al.Diagnostic accuracy of the Cogstate Brief Battery for prevalent MCI and prodromal AD (MCI A(+) T(+)) in a population-based sample. Alzheimers Dement2021; 17: 584–594.
13.
LimYYPietrzakRHBourgeatP, et al.Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and Abeta accumulation in cognitively normal older adults and adults with MCI. Arch Clin Neuropsychol2015; 30: 49–58.
14.
NathanPJLimYYAbbottR, et al.Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). Neurobiol Aging2017; 53: 1–10.
15.
PappKVRentzDMMaruffP, et al.The computerized cognitive composite (c3) in a4, an Alzheimer’s disease secondary prevention trial. J Prev Alzheimers Dis2021; 8: 59–67.
16.
HahnAKimYJKimHJ, et al.The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer's disease. Sci Rep2020; 10: 13583.
17.
ChinJKimDELeeH, et al.A validation study of the Inbrain CST: a tablet computer-based cognitive screening test for elderly people with cognitive impairment. J Korean Med Sci2020; 35: e292.
18.
ClarkCMSchneiderJABedellBJ, et al.Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA2011; 305: 275–283.
19.
FarrarG. Regional visual read inspection of [18F] flutemetamol brain images from end-of-life and amnestic MCI subjects. J Nucl Med2017; 58: 1250.
20.
JohnsonKASperlingRAGidicsinCM, et al.Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement2013; 9: S72–S83.
21.
KimHJChoHWerringDJ, et al.18F-AV-1451 PET imaging in three patients with probable cerebral amyloid angiopathy. J Alzheimers Dis2017; 57: 711–716.
22.
MartínezGFlickerLVernooijRW, et al.F-18 PET ligands for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev2017; 11: CD012884.
23.
ChoSHChoeYSKimYJ, et al.Concordance in detecting amyloid positivity between 18F-florbetaben and 18F-flutemetamol amyloid PET using quantitative and qualitative assessments. Sci Rep2020; 10: 19576.
24.
SabriOSeibylJRoweC, et al.Beta-amyloid imaging with florbetaben. Clin Transl Imaging2015; 3: 13–26.
25.
MountzJMLaymonCMCohenAD, et al.Comparison of qualitative and quantitative imaging characteristics of [11C] PiB and [18F] flutemetamol in normal control and Alzheimer's subjects. Neuroimage Clin2015; 9: 592–598.
26.
KlineRB. Principles and practice of structural equation modeling. 4th ed. New York: The Guilford Press, 2015.
27.
ThompsonB. Exploratory and confirmatory factor analysis: Understanding concepts and applications. Washington, DC: American Psychological Association, 2004.
28.
Nalbantoğlu YılmazF. Comparison of different estimation methods used in confirmatory factor analyses in non-normal data: a Monte Carlo study. Int Online J Educ Sci2019; 11: 131–140.
29.
DeLongERDeLongDMClarke-PearsonDL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics1988; 44: 837–845.
30.
ChunMYKimGHParkHK, et al.Predictive scale for amyloid PET positivity based on clinical and MRI variables in patients with amnestic mild cognitive impairment. J Clin Med2022; 11: 3433.
31.
KandelBMAvantsBBGeeJC, et al.Neuropsychological testing predicts cerebrospinal fluid amyloid-beta in mild cognitive impairment. J Alzheimers Dis2015; 46: 901–912.
32.
KoHIhmJJKimHG, et al.Cognitive profiling related to cerebral amyloid beta burden using machine learning approaches. Front Aging Neurosci2019; 11: 95.
33.
LeeJHByunMSYiD, et al.Prediction of cerebral amyloid with common information obtained from memory clinic practice. Front Aging Neurosci2018; 10: 309.
34.
LimYYMaruffPPietrzakRH, et al.Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain2014; 137: 221–231.
35.
PikeKESavageGVillemagneVL, et al.Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain2007; 130: 2837–2844.
36.
TosunDSchuffNMathisCA, et al.Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain2011; 134: 1077–1088.
37.
VanniniPHeddenTBeckerJA, et al.Age and amyloid-related alterations in default network habituation to stimulus repetition. Neurobiol Aging2012; 33: 1237–1252.
38.
RentzDMAmariglioREBeckerJA, et al.Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia2011; 49: 2776–2783.
39.
GrotheMJBarthelHSepulcreJ, et al.In vivo staging of regional amyloid deposition. Neurology2017; 89: 2031–2038.
40.
PalmqvistSSchollMStrandbergO, et al.Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun2017; 8: 1214.
41.
KesselsRPvan den BergERuisC, et al.The backward span of the Corsi Block-Tapping Task and its association with the WAIS-III Digit Span. Assessment2008; 15: 426–434.
42.
VonkJMTwaitELScholtenRJ, et al.Cross-sectional associations of amyloid burden with semantic cognition in older adults without dementia: a systematic review and meta-analysis. Mech Ageing Dev2020; 192: 111386.
43.
OssenkoppeleRSchonhautDRSchöllM, et al.Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain2016; 139: 1551–1567.
44.
FokkemaMGreiffS. How performing PCA and CFA on the same data equals trouble. Newburyport, MA: Hogrefe Publishing, 2017.
OECD/European Union/EC-JRC. Handbook on constructing composite indicators: Methodology and user guide. Paris: OECD Publishing, 2008.
47.
PetersonEDDeLongERMasoudiFA, et al.ACCF/AHA 2010 position statement on composite measures for healthcare performance assessment: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop a Position Statement on Composite Measures). Circulation2010; 121: 1780–1791.
48.
GoreRDialloSLynchC, et al.Augmenting bottom-up metamodels with predicates. J Artif Soc Soc Simul2017; 20: 4.
49.
JansenWJJanssenOTijmsBM, et al.Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurol2022; 79: 228–243.
50.
LandauSMHorngAFeroA, et al.Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. Neurology2016; 86: 1377–1385.
51.
RobertsROAakreJAKremersWK, et al.Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting. JAMA Neurol2018; 75: 970–979.
52.
VillemagneVLBurnhamSBourgeatP, et al.Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol2013; 12: 357–367.
53.
HatashitaSWakebeDKikuchiY, et al.Longitudinal assessment of amyloid-β deposition by [18F]-flutemetamol PET imaging compared with [11C]-PIB across the spectrum of Alzheimer’s disease. Front Aging Neurosci2019; 11: 251.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
